AbbVie Seeks EMA Approval for Subcutaneous SKYRIZI in Crohn's Disease

AbbVie has submitted an application to the European Medicines Agency (EMA) for SKYRIZI (risankizumab) as a subcutaneous induction treatment for adults with moderately to severely active Crohn's disease. This submission, supported by positive Phase 3 AFFIRM study data, aims to offer patients a more convenient subcutaneous injection option in addition to the current intravenous method. This could improve treatment accessibility and patient experience for those managing the chronic condition.